CN110139667A - 一种使胰高血糖素、胰岛素恢复正常平衡的方法 - Google Patents

一种使胰高血糖素、胰岛素恢复正常平衡的方法 Download PDF

Info

Publication number
CN110139667A
CN110139667A CN201780078124.3A CN201780078124A CN110139667A CN 110139667 A CN110139667 A CN 110139667A CN 201780078124 A CN201780078124 A CN 201780078124A CN 110139667 A CN110139667 A CN 110139667A
Authority
CN
China
Prior art keywords
plasminogen
group
insulin
expression
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078124.3A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN110139667A publication Critical patent/CN110139667A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本发明涉及一种使胰高血糖素、胰岛素恢复正常平衡的方法，包括给药受试者有效量的纤溶酶原，同时本发明涉及用于使胰高血糖素、胰岛素恢复正常平衡的药物。

Description

PCT国内申请，说明书已公开。

Claims (48)

  1. PCT国内申请，权利要求书已公开。
CN201780078124.3A 2016-12-15 2017-06-19 一种使胰高血糖素、胰岛素恢复正常平衡的方法 Pending CN110139667A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110171 2016-12-15
CNPCT/CN2016/110171 2016-12-15
PCT/CN2017/089066 WO2018107706A1 (zh) 2016-12-15 2017-06-19 一种使胰高血糖素、胰岛素恢复正常平衡的方法

Publications (1)

Publication Number Publication Date
CN110139667A true CN110139667A (zh) 2019-08-16

Family

ID=62557852

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780078131.3A Pending CN110121357A (zh) 2016-12-15 2017-06-19 一种治疗糖尿病的新方法
CN201780078168.6A Pending CN110198732A (zh) 2016-12-15 2017-06-19 一种促进胰岛素受体底物-2表达的方法
CN201780078122.4A Pending CN110366426A (zh) 2016-12-15 2017-06-19 一种促进胰岛素分泌的方法
CN201780078124.3A Pending CN110139667A (zh) 2016-12-15 2017-06-19 一种使胰高血糖素、胰岛素恢复正常平衡的方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201780078131.3A Pending CN110121357A (zh) 2016-12-15 2017-06-19 一种治疗糖尿病的新方法
CN201780078168.6A Pending CN110198732A (zh) 2016-12-15 2017-06-19 一种促进胰岛素受体底物-2表达的方法
CN201780078122.4A Pending CN110366426A (zh) 2016-12-15 2017-06-19 一种促进胰岛素分泌的方法

Country Status (8)

Country Link
US (4) US20190307861A1 (zh)
EP (4) EP3556383B1 (zh)
JP (6) JP2020510628A (zh)
CN (4) CN110121357A (zh)
CA (4) CA3047173A1 (zh)
DK (1) DK3556383T3 (zh)
TW (7) TW201822803A (zh)
WO (7) WO2018107708A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709771B2 (en) 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
EP3391902B1 (en) 2015-12-18 2023-10-18 Talengen International Limited Plasminogen for use in the treatment of diabetic angiocardiopathy
WO2017101868A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
CN110121357A (zh) * 2016-12-15 2019-08-13 泰伦基国际有限公司 一种治疗糖尿病的新方法
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000420A1 (en) * 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
CN101918548A (zh) * 2007-11-29 2010-12-15 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
WO1994001128A1 (en) 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
DK125693D0 (zh) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
BR9608326A (pt) 1995-04-26 2000-03-08 Childrens Medical Center Fragmentos de angiostatina e angiostatina agregada e processos de uso.
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US5955627A (en) 1996-12-16 1999-09-21 Kuraray Co., Ltd. Process for the preparation of cyclopropylacetylene derivatives
JP3561154B2 (ja) 1997-12-26 2004-09-02 株式会社東芝 放送受信装置および契約管理装置
US6728260B2 (en) 1998-06-26 2004-04-27 Intel Corporation Switch and/or router unit
CN1191856C (zh) 1998-09-29 2005-03-09 勒芬研究与发展公司 可在体内减少α2－抗纤溶酶的化合物在制备用于治疗局部缺血性中风的组合物中的用途
WO2000044391A2 (en) 1999-01-28 2000-08-03 The Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US20030014787P1 (en) 1999-03-31 2003-01-16 Olesen L. Pernille Floribunda rose variety 'POULfeld'
WO2001024815A1 (en) 1999-10-07 2001-04-12 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US6596785B2 (en) 2001-07-17 2003-07-22 Foamex L.P. Ink retaining foam structure
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
JP2005525798A (ja) 2002-02-06 2005-09-02 トロムスドルフ ゲーエムベーハー ウント コー．カーゲー アルツナイミッテル 微生物内での組み換えタンパク質の生産方法
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
EP2322203A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
US7075933B2 (en) 2003-08-01 2006-07-11 Nortel Networks, Ltd. Method and apparatus for implementing hub-and-spoke topology virtual private networks
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN1946352A (zh) 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
SI1740698T1 (sl) 2004-04-22 2010-11-30 Talecris Biotherapeutics Inc Rekombinantno modificiran plazmin
EP1781641A1 (en) 2004-08-23 2007-05-09 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
CN101039936A (zh) 2004-08-23 2007-09-19 惠氏公司 作为i－型纤溶酶原激活剂抑制剂(pai－1)调节剂用于治疗血栓形成和心血管疾病的唑基－萘基酸
CN101227918A (zh) 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US8064439B2 (en) 2005-06-30 2011-11-22 Cisco Technology, Inc. Method and system for call processing
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
CN100529085C (zh) 2005-12-30 2009-08-19 上海新生源医药研究有限公司 重组人纤溶酶原Kringle 5(hk5)生产方法
CN101002888A (zh) * 2006-01-16 2007-07-25 陈维森 复方糖尿康
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
CN101563100B (zh) * 2006-08-28 2013-08-07 李季男 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
RU2010120675A (ru) 2007-10-23 2011-11-27 Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) Ингибитор продуцирования pai-1
US20090208448A1 (en) * 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
JP2009196927A (ja) 2008-02-21 2009-09-03 Chemo Sero Therapeut Res Inst 血管障害に起因する網膜障害の進展阻害または治療剤
WO2010125148A2 (en) 2009-04-30 2010-11-04 Catherine Blondel Methods for treating ocular conditions
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN102250210B (zh) 2010-05-21 2014-05-28 厦门大学 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
DK2661493T3 (en) 2011-01-05 2016-07-18 Thrombogenics Nv PLASMINOGEN AND PLASMIN VARIANS
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
AU2012296884B2 (en) * 2011-08-12 2015-02-05 Thrombogenics N.V. Plasminogen and plasmin variants
EP2914575B1 (en) * 2012-10-31 2020-10-14 The Regents Of The University Of Michigan Plasminogen activator-1 inhibitors and methods of use thereof
ES2770507T3 (es) 2013-08-13 2020-07-01 Sanofi Sa Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
US20160245808A1 (en) * 2013-10-17 2016-08-25 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
CN104789544B (zh) 2014-01-16 2019-11-26 中国科学院福建物质结构研究所 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途
CA2971359C (en) 2014-12-19 2024-04-02 Prometic Biotherapeutics, Inc. Pharmaceutical composition comprising plasminogen and uses thereof
CN108472342B (zh) 2015-12-18 2022-11-15 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
WO2017101868A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
US10709771B2 (en) 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
CN110121357A (zh) 2016-12-15 2019-08-13 泰伦基国际有限公司 一种治疗糖尿病的新方法
TW201822809A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療高脂血症的方法
EP3725326A4 (en) 2017-12-15 2021-03-03 Talengen International Limited METHOD AND MEDICATION FOR PREVENTING OR TREATING ARTHROSIS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000420A1 (en) * 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
CN101918548A (zh) * 2007-11-29 2010-12-15 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARTHUR MIRSK等: "The destruction of glucagon, adrenocorticotropin and somatotropin by human blood plasma", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *
AURELIA LUGEA等: "Pancreas Recovery Following Caerulein-induced Pancreatitis is Impaired in Plasminogen Deficient Mice", 《GASTROENTEROLOGY》 *
BUTERA D等: "plasminogen isoform 1 precursor [Homo sapiens]", 《GENBANK》 *
RAMZI A. AJJAN等: "Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity", 《BLOOD》 *

Also Published As

Publication number Publication date
TW201822807A (zh) 2018-07-01
TWI763680B (zh) 2022-05-11
US20190307861A1 (en) 2019-10-10
JP2022166026A (ja) 2022-11-01
CA3047176A1 (en) 2018-06-21
US20190314463A1 (en) 2019-10-17
TW201822804A (zh) 2018-07-01
CA3047173A1 (en) 2018-06-21
EP3556392A4 (en) 2020-09-23
TW201822808A (zh) 2018-07-01
TWI763681B (zh) 2022-05-11
EP3556390A4 (en) 2020-09-09
EP3556384B1 (en) 2024-04-10
EP3556383A1 (en) 2019-10-23
WO2018107701A1 (zh) 2018-06-21
JP7175270B2 (ja) 2022-11-18
WO2018107703A1 (zh) 2018-06-21
TW201822802A (zh) 2018-07-01
EP3556392A1 (en) 2019-10-23
EP3556383B1 (en) 2024-04-10
US20190314465A1 (en) 2019-10-17
JP2020502150A (ja) 2020-01-23
TWI642442B (zh) 2018-12-01
JP7171572B2 (ja) 2022-11-15
EP3556384A1 (en) 2019-10-23
EP3556383A4 (en) 2020-09-09
EP3556384A4 (en) 2020-09-23
TW201822800A (zh) 2018-07-01
CN110198732A (zh) 2019-09-03
US11311607B2 (en) 2022-04-26
JP2022166028A (ja) 2022-11-01
CN110121357A (zh) 2019-08-13
US20190314464A1 (en) 2019-10-17
TWI738799B (zh) 2021-09-11
EP3556390B1 (en) 2024-04-03
JP2020502140A (ja) 2020-01-23
JP2020510628A (ja) 2020-04-09
JP2020502151A (ja) 2020-01-23
CN110366426A (zh) 2019-10-22
CA3047172A1 (en) 2018-06-21
WO2018107702A1 (zh) 2018-06-21
CA3047177A1 (en) 2018-06-21
WO2018107706A1 (zh) 2018-06-21
WO2018107705A1 (zh) 2018-06-21
EP3556392B1 (en) 2024-04-17
EP3556390A1 (en) 2019-10-23
TW201822803A (zh) 2018-07-01
DK3556383T3 (da) 2024-05-13
TWI644682B (zh) 2018-12-21
TW201822801A (zh) 2018-07-01
WO2018107708A1 (zh) 2018-06-21
TWI669130B (zh) 2019-08-21
US11129880B2 (en) 2021-09-28
CA3047176C (en) 2021-11-30
WO2018107704A1 (zh) 2018-06-21

Similar Documents

Publication Publication Date Title
CN110139667A (zh) 一种使胰高血糖素、胰岛素恢复正常平衡的方法
CN108210912A (zh) 一种使胰高血糖素、胰岛素恢复正常平衡的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination